- MindMed (MNMD, Financial) issues inducement grants to three new non-executive employees.
- The grants include options to purchase 121,500 common shares, effective April 21, 2025.
- Options vest over four years, with 25% after the first year and 75% in monthly increments.
Mind Medicine Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on developing novel treatments for brain health disorders, has announced the issuance of inducement grants to three newly hired non-executive employees. These grants involve options to purchase a total of 121,500 common shares of the company, effective April 21, 2025.
The exercise price for these options will be determined by the closing price of MindMed's common shares on April 18, 2025. The vesting schedule is spread over four years, with 25% of the options vesting after the first year, and the remaining 75% vesting in substantially equal monthly increments over the subsequent three years, contingent upon continued employment. MindMed's Compensation Committee approved these grants on April 16, 2025, in compliance with NASDAQ Rule 5635(c)(4).
MindMed continues to advance its mission to become a global leader in developing and delivering innovative treatments for brain health disorders, leveraging its position on the NASDAQ under the symbol MNMD.
